Research Analysts’ Weekly Ratings Changes for Gilead Sciences (GILD)

Several brokerages have updated their recommendations and price targets on shares of Gilead Sciences (NASDAQ: GILD) in the last few weeks:

  • 2/12/2024 – Gilead Sciences had its price target lowered by analysts at Oppenheimer Holdings Inc. from $115.00 to $105.00. They now have an “outperform” rating on the stock.
  • 2/12/2024 – Gilead Sciences had its price target lowered by analysts at Barclays PLC from $85.00 to $80.00. They now have an “equal weight” rating on the stock.
  • 2/7/2024 – Gilead Sciences had its price target lowered by analysts at Royal Bank of Canada from $78.00 to $76.00. They now have a “sector perform” rating on the stock.
  • 2/7/2024 – Gilead Sciences had its price target lowered by analysts at Cantor Fitzgerald from $80.00 to $78.00. They now have a “neutral” rating on the stock.
  • 2/7/2024 – Gilead Sciences had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $84.00. They now have an “equal weight” rating on the stock.
  • 1/23/2024 – Gilead Sciences had its price target raised by analysts at Barclays PLC from $82.00 to $85.00. They now have an “equal weight” rating on the stock.

Gilead Sciences Trading Up 1.1 %

Shares of Gilead Sciences stock opened at $74.45 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $72.81 and a 12-month high of $87.86. The company has a quick ratio of 1.16, a current ratio of 1.46 and a debt-to-equity ratio of 1.08. The business’s 50 day moving average is $80.67 and its 200-day moving average is $78.19. The stock has a market cap of $92.77 billion, a P/E ratio of 16.54, a P/E/G ratio of 0.96 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.67 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 7.08 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a $0.77 dividend. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.14%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is 66.67%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 8,242 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 8,242 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. 0.21% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Capital World Investors boosted its position in shares of Gilead Sciences by 5.8% during the 2nd quarter. Capital World Investors now owns 80,929,316 shares of the biopharmaceutical company’s stock worth $6,237,075,000 after acquiring an additional 4,429,076 shares in the last quarter. State Street Corp boosted its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. State Street Corp now owns 59,317,162 shares of the biopharmaceutical company’s stock worth $4,571,574,000 after acquiring an additional 1,514,894 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 24,212,636 shares of the biopharmaceutical company’s stock worth $1,861,363,000 after acquiring an additional 447,585 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Gilead Sciences by 324.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Gilead Sciences by 2.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,452,922 shares of the biopharmaceutical company’s stock valued at $1,345,097,000 after purchasing an additional 440,718 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.